NHS England agrees to cover Enhertu for HER2-low metastatic breast cancer
NHS England agreed to cover Enhertu for patients with HER2-low metastatic breast cancer. This decision applies across the country and is associated with an estimated 1,000 eligible people. Implementation details are pending and the patient count is a projection rather than actual uptake.
Why it matters
This addresses limited treatment options for HER2-low metastatic breast cancer by expanding access to a targeted therapy.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news